Syncria (GlaxoSmithKline) shows mixed results in Phase III studies of Type 2 Diabetes patients

New results are reported for HARMONY 6, a 52-week randomised study comparing Syncria (albiglutide), from GlaxoSmithKline, to Lispro among patients with Type 2 Diabetes who were inadequately controlled on intermediate or long-acting insulin. In addition to previously reported results, the effect on HbA1c was maintained on continued treatment at 52 weeks (reduction from baseline of 1.01% vs 0.85%). In addition, the proportion of patients achieving a clinically meaningful HbA1c target level (ADA goal of <7.0%) by week 52 was 45% in the albiglutide arm compared to 30% (p="NS" for treatment difference) in the lispro arm. results of harmony 7, a 32-week head-to-head study comparing syncria (50mg) to once-daily liraglutide (1.8mg), demonstrated a statistically significant reduction in hba1c from baseline but did not meet the pre-specified primary endpoint of non-inferiority to liraglutide. however the proportion of patients achieving a clinically meaningful hba1c target level of more than 7.0 at week 32 was higher in the liraglutide arm (52%) compared to the albiglutide arm (42%). results were presented at the american diabetes association meeting.>